 -- Received European Commission authorization of IMCIVREE for treatment of obesity and control of hunger associated with POMC, PCSK1 and LEPR deficiencies -- -- Setmelanotide selected for evaluation as a Highly Specialised Technology by Great Britains National Institute for Health and Care Excellence -- -- On track to submit sNDA to FDA and MAA Type II amendment to EMA for setmelanotide in BBS and Alström syndromes in 2H 2021 -- -- Five new Phase 2 and 3 clinical trials planned to initiate in 2H 2021 -- -- Management to host conference call at 8 a.m. ET -- BOSTON, Aug. 03, 2021 GLOBE NEWSWIRE -- Rhythm Pharmaceuticals, Inc. Nasdaq: RYTM, a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today reported financial results and provided a business update for the second quarter ended June 30, 2021. 